Method for reducing toxicity of combined chemotherapies

Details Method for reducing toxicity of combined chemotherapies Method for reducing toxicity of combined chemotherapies

2005-08-09

2005-08-09

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S449000, C514S002600, C514S365000, C514S388000, C514S397000, C514S690000, C514S269000, C514S050000, C536S006400, C536S017200, C536S018400, C536S018500, C536S004100, C424S178100, C424S145100, C549S214000, C435S069100, C435S810000

Reexamination Certificate

active

06927211

ABSTRACT:
Compositions and methods are provided for use in the treatment of cancer.

REFERENCES:
patent: 4203900 (1980-05-01), Kaiser
patent: 4206221 (1980-06-01), Miller et al.
patent: 4303439 (1981-12-01), Howe et al.
patent: 4354029 (1982-10-01), Kaiser et al.
patent: 4360678 (1982-11-01), Howe et al.
patent: 4443611 (1984-04-01), Kaiser
patent: 4543414 (1985-09-01), Carson
patent: 4743700 (1988-05-01), Jamm et al.
patent: 4814470 (1989-03-01), Colin et al.
patent: 4857653 (1989-08-01), Colin et al.
patent: 4876399 (1989-10-01), Holton et al.
patent: 4877881 (1989-10-01), Belliotti et al.
patent: 4924002 (1990-05-01), Kostlan
patent: 4924011 (1990-05-01), Denis et al.
patent: 4924012 (1990-05-01), Colin et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 5015744 (1991-05-01), Holtan
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5128478 (1992-07-01), Ito et al.
patent: 5136060 (1992-08-01), Holtan
patent: 5194635 (1993-03-01), Kingston et al.
patent: 5208237 (1993-05-01), Hewawasam et al.
patent: 5227400 (1993-07-01), Holton et al.
patent: 5243045 (1993-09-01), Holton et al.
patent: 5254580 (1993-10-01), Chen
patent: 5264591 (1993-11-01), Bombardelli et al.
patent: 5272171 (1993-12-01), Ueda et al.
patent: 5278324 (1994-01-01), Kingston et al.
patent: 5283253 (1994-02-01), Holton et al.
patent: 5296506 (1994-03-01), Kingston
patent: 5319112 (1994-06-01), Kingston et al.
patent: 5352806 (1994-10-01), Gunawardana et al.
patent: 5399726 (1995-03-01), Holton et al.
patent: 5420337 (1995-05-01), Patel et al.
patent: 5440056 (1995-08-01), Klein et al.
patent: 5449790 (1995-09-01), Zheng et al.
patent: 5468769 (1995-11-01), Klein et al.
patent: 5476954 (1995-12-01), Borzat et al.
patent: 5556878 (1996-09-01), Kelly et al.
patent: 5580997 (1996-12-01), Bouchard et al.
patent: 5589502 (1996-12-01), Tsujihara et al.
patent: 5616739 (1997-04-01), Mas et al.
patent: 5618952 (1997-04-01), Holton et al.
patent: 5621121 (1997-04-01), Cammercon et al.
patent: 5635531 (1997-06-01), Chen
patent: 5637732 (1997-06-01), Holton et al.
patent: 5646176 (1997-07-01), Golik et al.
patent: 5670658 (1997-09-01), Bastart
patent: 5677470 (1997-10-01), Tsujihara et al.
patent: 5710287 (1998-01-01), Holton et al.
patent: 5721268 (1998-02-01), Holton et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5728725 (1998-03-01), Holton et al.
patent: 5760252 (1998-06-01), Holton et al.
patent: 5767296 (1998-06-01), Terasawa et al.
patent: 5773461 (1998-06-01), Wittma et al.
patent: 5808102 (1998-09-01), Poss et al.
patent: 5840931 (1998-11-01), Bouchard et al.
patent: 5847170 (1998-12-01), Bouchard et al.
patent: 5889043 (1999-03-01), Bouchard et al.
patent: 5908835 (1999-06-01), Bissery
patent: 6005120 (1999-12-01), Holton et al.
patent: 6020507 (2000-02-01), Gibson
patent: 6043375 (2000-03-01), Borzat et al.
patent: 6072060 (2000-06-01), Suidell et al.
patent: 6096909 (2000-08-01), Ojima
patent: 6100411 (2000-08-01), Ojima
patent: 6214863 (2001-04-01), Bissery
patent: 6239167 (2001-05-01), Bissery
patent: 6248908 (2001-06-01), Kant
patent: 6340701 (2002-01-01), Chari et al.
patent: 6353120 (2002-03-01), Kant
patent: 1061330 (1979-08-01), None
patent: 1695918 (1971-05-01), None
patent: 2919891 (1980-12-01), None
patent: 0 359 516 (1994-08-01), None
patent: 0 428 376 (1996-01-01), None
patent: 0 537 905 (1996-03-01), None
patent: 0 537 905 (1996-03-01), None
patent: 0 505 047 (1996-04-01), None
patent: 0 505 047 (1996-04-01), None
patent: 0 400 971 (1998-07-01), None
patent: 0 400 971 (1998-07-01), None
patent: 0 604 910 (2004-07-01), None
patent: 55-145650 (1980-11-01), None
patent: 60-222416 (1985-11-01), None
patent: 61-005022 (1986-01-01), None
patent: 61-115022 (1986-06-01), None
patent: 61-51578 (1986-11-01), None
patent: 9208572 (1997-08-01), None
patent: WO 90/02738 (1990-03-01), None
patent: WO 92/09589 (1992-06-01), None
patent: WO 92/19765 (1992-11-01), None
patent: WO 94/07876 (1994-04-01), None
patent: WO 94/13655 (1994-06-01), None
patent: WO 94/14787 (1994-07-01), None
patent: WO 95/03265 (1995-02-01), None
patent: WO 96/00724 (1996-01-01), None
patent: WO 96/13495 (1996-05-01), None
patent: WO 96/14309 (1996-05-01), None
patent: WO 96/23779 (1996-08-01), None
patent: WO 97/09979 (1997-03-01), None
patent: WO 97/23472 (1997-07-01), None
patent: WO 97/32578 (1997-09-01), None
patent: WO 97/32869 (1997-09-01), None
patent: WO 98/01435 (1998-01-01), None
patent: WO 98/22451 (1998-05-01), None
patent: WO 99/33462 (1999-07-01), None
Loshak. “New drug combination enhances treatment for advanced breast cancer.” DG-Dispatch-ECCO, online: www.pslgroup.com/dg/12c452.html, Sep. 17, 1999, pp. 1-2.
Donnelli, M.G., et al; Pharmacokinetics of anticancer agents in patients with impaired liver function; European Journal of Cancer; Pergamon Press; Oxford, Great Britain; vol. 34, No. 1; Jan. 1998.
ECCO: Taxol/doxorubicin Improves Survival in Metastatic Breast Cancer; Doctor's Guide, 'Online!, Sep. 22, 1999; retrieved from the Internet: www.pslgroup.com/dg/13144a.htm; retrieved Nov. 6, 2002.
DG Dispatch—ECCO: New Drug Combination Enhances Treatment for Advanced Breast Cancer; Doctor's Guide; 'Online!; Sep. 19, 1999; retrieved from the Internet: www.pslgroup.com/dg/12c452.htm.
Sparano, “Doxorubicin/Taxane combinations: Cardiac toxicity and pharmacokinetics.” Seminars in Oncology, vol. 26, No. 3, Suppl. 9 (Jun. 1999), pp. 14-19.
Gianni et al., “Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel patients with breast cancer.” Journal of clinical oncology, vol. 15, No. 5 (May 1997) pp. 1906-1915.
Zoli et al. “In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.” Breast Cancer Research and Treatment, 34, 1995, pp. 63-39.
Wahl et al. “Selective tumor sensitization to taxancs with the mab-drug conjugate CBR96-doxorubicin.” Abstract: Int. J. Cancer vol. 4 (Aug. 15, 2001), pp. 590-600.

Affiliated with

Also associated with

Rating

Method for reducing toxicity of combined chemotherapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for reducing toxicity of combined chemotherapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing toxicity of combined chemotherapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3521132